Evidence map›Paper›PMID 30452522›Full record

ArticleJAMA neurology2019

Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years.

Rosalyn Hithersay, Carla M Startin, Sarah Hamburg, Kin Y Mok, John Hardy, Elizabeth M C Fisher, Victor L J Tybulewicz, Dean Nizetic, André Strydom

3 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in JAMA neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 97 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 4 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04165109 recruitingnot on this mapstarted 2021, after this paper: background citation

Alzheimer's Clinical Trial Consortium for Down Syndrome (ACTC-DS) Trial-Ready Cohort - Down Syndrome (TRC-DS)

TypeobservationalSponsorUniversity of Southern CaliforniaRan2021 to 2027Enrolled550ConditionsDown Syndrome, Alzheimer Disease, Dementia
NCT07047963 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Neuropsychological Evaluation in Intellectual Disability

TypeobservationalSponsorCentral Hospital, Nancy, FranceRan2025 to 2026Enrolled40ConditionsDown Syndrome (Trisomy 21), Neuropsychology, Cognitive Aging, Alzheimer DiseaseArmsENDI (Neuropsychological Evaluation in Intellectual Disability)
NCT07531940 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome

TypeinterventionalSponsorUniversity Hospitals Cleveland Medical CenterRan2026 to 2028Enrolled25ConditionsDown Syndrome, Intellectual DisabilityArmsMemantine
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 168 citations in OpenAlex.

  1. Early Markers for Dementia in the Intellectual Disability Population: A Systematic Literature Review.Journal of applied research in intellectual disabilities : JARID · 2025
    Pooled it
  2. Pooled it
  3. Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Structural MRI across lifespan reveals differential thalamic trajectories in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. Review
  14. Article
  15. Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  16. Article
  17. Article
  18. Factors impacting survival in individuals with Down syndrome-associated Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  19. Caregiver Interviews Regarding Health in Down Syndrome.American journal of medical genetics. Part A · 2026
    Observational
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Rosalyn HithersayDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.
Carla M StartinDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.
Sarah HamburgDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.
Kin Y MokLondon Down Syndrome Consortium, London, England.
John HardyLondon Down Syndrome Consortium, London, England.
Elizabeth M C FisherLondon Down Syndrome Consortium, London, England.
Victor L J TybulewiczLondon Down Syndrome Consortium, London, England.
Dean NizeticLondon Down Syndrome Consortium, London, England.
André StrydomDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England.
University College London · GBKing's College London · GBQueen Mary University of London · GBThe Francis Crick Institute · GB

Funding

Medical Research Council G0400017Medical Research Council G0400149Medical Research Council G0500288Medical Research Council G0601056Medical Research Council G0801110Medical Research Council MC_UP_1502/3Medical Research Council MR/R024901/1Medical Research Council MR/S011277/1Wellcome Trust 098330
6 · The paper itself

Abstract

Importance: This work quantifies the fatal burden of dementia associated with Alzheimer disease in individuals with Down syndrome (DS). Objective: To explore the association of dementia associated with Alzheimer disease with mortality and examine factors associated with dementia in adults with DS. Design, Settings and Participants: Prospective longitudinal study in a community setting in England. Data collection began March 29, 2012. Cases were censored on December 13, 2017. The potential sample consisted of all adults 36 years and older from the London Down Syndrome Consortium cohort with 2 data times and dementia status recorded (N = 300); 6 withdrew from study, 28 were lost to follow-up, and 55 had a single data collection point at time of analysis. The final sample consisted of 211 participants, with 503.92 person-years' follow-up. Exposures: Dementia status, age, sex, APOE genotype, level of intellectual disability, health variables, and living situation. Main Outcomes and Measures: Crude mortality rates, time to death, and time to dementia diagnosis with proportional hazards of predictors. Results: Of the 211 participants, 96 were women (45.5%) and 66 (31.3%) had a clinical dementia diagnosis. Twenty-seven participants (11 female; mean age at death, 56.74 years) died during the study period. Seventy percent had dementia. Crude mortality rates for individuals with dementia (1191.85 deaths per 10 000 person-years; 95% CI, 1168.49-1215.21) were 5 times higher than for those without (232.22 deaths per 10 000 person-years; 95% CI, 227.67-236.77). For those with dementia, APOE ε4 carriers had a 7-fold increased risk of death (hazard ratio [HR], 6.91; 95% CI, 1.756-27.195). For those without dementia, epilepsy with onset after age 36 years was associated with mortality (HR, 9.66; 95% CI, 1.59-58.56). APOE ε4 carriers (HR, 4.91; 95% CI, 2.53-9.56), adults with early-onset epilepsy (HR, 3.61; 95% CI, 1.12-11.60), multiple health comorbidities (HR, 1.956; 95% CI, 1.087-3.519), and those living with family (HR, 2.14; 95% CI, 1.08-4.20) received significantly earlier dementia diagnoses. Conclusions and Relevance: Dementia was associated with mortality in 70% of older adults with DS. APOE ε4 carriers and/or people with multiple comorbid health conditions were at increased risk of dementia and death, highlighting the need for good health care. For those who died without a dementia diagnosis, late-onset epilepsy was the only significant factor associated with death, raising questions about potentially undiagnosed dementia cases in this group.

Indexed as

MortalityAdultAge of OnsetApolipoprotein E4ComorbidityDementiaDown SyndromeEnglandEpilepsyFemaleHeterozygoteHumansLongitudinal StudiesMaleMiddle AgedSurvival AnalysisApolipoprotein E4

Identifiers

PMID30452522
PMCPMC6439956
OpenAlexW2901207373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.